Department of Cardiology, Emory University School of Medicine, 1364 Clifton Road, Atlanta, GA 30322, USA; Rollins School of Public Health, Emory University, Atlanta, GA, USA.
Department of Hematology and Medical Oncology, Emory University School of Medicine, 1364 Clifton Road, Atlanta, GA 30322, USA; Winship Cancer Institute, Emory University School of Medicine, 1365 Clifton Road Atlanta, GA 30322, USA.
Heart Fail Clin. 2019 Jan;15(1):65-75. doi: 10.1016/j.hfc.2018.08.007.
Heart failure and breast cancer have shared risks and morbidities. Multimodality therapies for breast cancer, including conventional chemotherapy, targeted therapeutics, radiation therapy, and hormonal agents, may make patients more susceptible to asymptomatic left ventricular dysfunction and clinical heart failure during and after treatment. New or preexisting left ventricular dysfunction may lead to interruptions in cancer treatment and limit options of breast cancer systemic therapy, leading to adverse outcomes. Early recognition and management of cardiovascular risk factors before, during, and after cancer treatment are of utmost importance. This review presents advances, challenges, and opportunities for cardiovascular care in contemporary breast cancer treatment.
心力衰竭和乳腺癌有共同的风险和并发症。乳腺癌的多模态治疗方法，包括常规化疗、靶向治疗、放射治疗和激素制剂，可能会使患者在治疗期间和治疗后更容易出现无症状左心室功能障碍和临床心力衰竭。新的或预先存在的左心室功能障碍可能导致癌症治疗中断，并限制乳腺癌系统治疗的选择，从而导致不良后果。在癌症治疗之前、期间和之后，早期识别和管理心血管危险因素至关重要。本文综述了当代乳腺癌治疗中心血管护理的进展、挑战和机遇。
